Mats Magnusson, Ph.D.

Chief Operations Officer

Portrait-of-Mats-Magnusson_Pharmetheus

Bio

  • Co-founded Pharmetheus in 2012, serving as Chief Operations Officer, actively working in client projects
  • Expertise includes reproducible reporting, pediatrics, and trial design across therapeutic areas
  • Previously worked as Consultant and Senior Consultant at Exprimo NV, Sweden, where he interacted with clients and provided pharmacokinetic, pharmacodynamic, disease modeling and simulation services to drug development programs in various therapeutic areas, and as Pharmacometrician at Pfizer PGRD, UK
  • M.Sc. in Pharmacy (2001) and Ph.D. in Biopharmaceutical Sciences (2007) from Uppsala University, Sweden
LinkedInGoogle Scholar

Pharmetheus affiliated publications

An Item Response Theory Model with Bounded Integer Subcomponents to Describe the Mayo Clinic Subscores in Patients with Ulcerative Colitis [2]A platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology frameworkWriting reports of modelling and simulation analysis: Our experience in the field of pharmacometricsPopulation Pharmacokinetics and Exposure-Response for Dapirolizumab Pegol From a Phase 2b Trial in Patients With Systemic Lupus ErythematosusPopulation Pharmacokinetics of Tenecteplase in Patients With Acute Myocardial Infarction and Application to Patients With Acute Ischemic StrokeExposure-Efficacy Analyses of Nintedanib in Patients with Chronic Fibrosing Interstitial Lung DiseaseComparison of Quality of Urinary Bladder Filling in CT Urography with Different Doses of Furosemide in the Work-Up of Patients with Macroscopic HematuriaPopulation Pharmacokinetic and Exposure-Response Models for Dapirolizumab Pegol in Patients with Systemic Lupus ErythematosusBridging Physiologically Based Pharmacokinetic (PBPK) and Population Pharmacokinetic (PopPK) Analyses in Paediatric Drug Development: A Case Study Based on Intravenous EsomeprazolePopulation PK and PASI Exposure-Response Modelling for Certolizumab Pegol in Patients with Chronic Plaque PsoriasisPharmTeX: a LaTeX-Based Open-Source Platform for Automated Reporting Workflow